LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

LLY

737.79

+2.36%↑

JNJ

154.98

+1.05%↑

ABBV

185.51

+0.1%↑

NVO

71.33

+2.71%↑

UNH

300.93

+0.94%↑

Search

Iovance Biotherapeutics Inc

Closed

SectorHealthcare

1.75 -3.31

Overview

Share price change

24h

Current

Min

1.75

Max

1.77

Key metrics

By Trading Economics

Income

-38M

-116M

Sales

-24M

49M

EPS

-0.36

Profit margin

-235.51

Employees

838

EBITDA

-35M

-110M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+555.74% upside

Dividends

By Dow Jones

Next Earnings

7 sie 2025

Market Stats

By TradingEconomics

Market Cap

-574M

594M

Previous open

5.06

Previous close

1.75

News Sentiment

By Acuity

50%

50%

151 / 381 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Iovance Biotherapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 maj 2025, 10:30 UTC

Top News

Pension Funds Won't Save the Bond Market -- Heard on the Street -- WSJ

31 maj 2025, 06:30 UTC

Earnings

5 Things We've Learned From Retail Earnings -- Barrons.com

31 maj 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 maj 2025, 23:51 UTC

Acquisitions, Mergers, Takeovers

Trump Raises Steel Tariffs, Saying U.S. Steel Will Remain U.S.-Controlled -- Update

30 maj 2025, 21:30 UTC

Top News

Stocks Shrug Off Trade War to Post Best Month Since 2023 -- WSJ

30 maj 2025, 21:15 UTC

Top News

The Score: E.l.f. Beauty, Tesla, Nvidia, and More Stocks That Defined the Week -- WSJ

30 maj 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

30 maj 2025, 20:44 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman Is Killing It. A New ETF Will Track His Investments. -- Barrons.com

30 maj 2025, 20:24 UTC

Top News

Major U.S. Stock Indexes Finish About Flat; U.S.-China Trade Friction Renews -- WSJ

30 maj 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 maj 2025, 19:44 UTC

Market Talk

Gold Breaks 4-Month Winning Streak -- Market Talk

30 maj 2025, 19:38 UTC

Market Talk

Companies Delay or Cancel $14B In Clean-Energy Investments -- Market Talk

30 maj 2025, 19:29 UTC

Earnings
Acquisitions, Mergers, Takeovers

NRG Energy and UnitedHealth Are the S&P 500's Best and Worst for May. Here's Why. -- Barrons.com

30 maj 2025, 19:14 UTC

Market Talk

Oil Settles Lower Ahead of OPEC+ Output Decision -- Market Talk

30 maj 2025, 19:05 UTC

Market Talk

U.S. Natural Gas Futures Fall Awaiting Hotter Weather -- Market Talk

30 maj 2025, 18:51 UTC

Market Talk

Canada's Retaliatory Tariffs Help Fuel Sizable Rise in Tax Revenue -- Market Talk

30 maj 2025, 18:37 UTC

Market Talk
Earnings

Costco Well Positioned for Sustainable Growth, UBS Says -- Market Talk

30 maj 2025, 18:04 UTC

Top News

S&P 500 Falls After More Trump-China Friction -- WSJ

30 maj 2025, 17:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 maj 2025, 17:47 UTC

Market Talk

Time for BoC Gov. Macklem to Cut Rates, Desjardins Says -- Market Talk

30 maj 2025, 17:40 UTC

Acquisitions, Mergers, Takeovers

Trump Is Praising His U.S. Steel Deal. No One Is Sure What It Means -- WSJ

30 maj 2025, 17:38 UTC

Market Talk

U.S: Oil Rig Count Falls for Fifth Straight Week -- Market Talk

30 maj 2025, 17:31 UTC

Market Talk

Costco Well Positioned to Gain Share Amid Tariffs, Baird Says -- Market Talk

30 maj 2025, 17:14 UTC

Top News

American Consumers Are Still Gloomy on the Economy -- 3rd Update

30 maj 2025, 16:31 UTC

Earnings

Ulta Beauty Stock Is Rising. Earnings Strength Was More Than Cosmetic. -- Barrons.com

30 maj 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

30 maj 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

30 maj 2025, 16:16 UTC

Top News

S&P 500 Falls After Trump Hits Out at China -- WSJ

30 maj 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 maj 2025, 16:14 UTC

Top News

HSBC Retreats From Banking Smaller U.S. Businesses -- WSJ

Peer Comparison

Price change

Iovance Biotherapeutics Inc Forecast

Price Target

By TipRanks

555.74% upside

12 Months Forecast

Average 12 USD  555.74%

High 25 USD

Low 2 USD

Based on 14 Wall Street analysts offering 12 month price targets forIovance Biotherapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

14 ratings

9

Buy

5

Hold

0

Sell

Technical Score

By Trading Central

3.0208 / 3.5Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

151 / 381 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.